HOLD. This company has too many possibilities to pass on it's current price.....I did a lot of DD prior to going "all in" on this stock. The drop from 4 to 1.2 had placed too much valuation on the trial results and VJ's moves (or lack of). Relative to the industry and the potential with the trials in the hopper, this should be a $6 stock in the current market. When positive trial results come in, the stock should see 12-15.
This could be one of those companies that sell for a $1.00 one year and sell for $10.00 the next . Only takes a good herpes report and on to $35.00. With failure, a non viral dna vaccine with Vaxfectin will be bought out for $12 to $15. To sell at this price is foolish but do what ever you feel is best.